{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:22:50Z","timestamp":1787826170100,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04217-w","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:27:10Z","timestamp":1749054430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?"],"prefix":"10.1186","volume":"26","author":[{"given":"Hamad","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrak","family":"Alahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahd","family":"Al-Mulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"4","key":"4217_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","volume":"59","author":"BL Furman","year":"2012","unstructured":"Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon. 2012;59(4):464\u201371.","journal-title":"Toxicon"},{"issue":"11","key":"4217_CR2","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/oby.23563","volume":"30","author":"S Sarma","year":"2022","unstructured":"Sarma S, Palcu P. Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis. Obes (Silver Spring). 2022;30(11):2111\u201321.","journal-title":"Obes (Silver Spring)"},{"issue":"4","key":"4217_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"2","key":"4217_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2215\/CJN.0000000584","volume":"20","author":"L Mendonca","year":"2024","unstructured":"Mendonca L, Moura H, Chaves PC, Neves JS, Ferreira JP. The impact of Glucagon-Like Peptide-1 receptor agonists on kidney outcomes: A Meta-Analysis of randomized Placebo-Controlled trials. Clin J Am Soc Nephrol. 2024;20(2):159\u201368.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4217_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"4217_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"4217_CR7","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","volume":"138","author":"JFE Mann","year":"2018","unstructured":"Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;138(25):2908\u201318.","journal-title":"Circulation"},{"issue":"19","key":"4217_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"key":"4217_CR9","doi-asserted-by":"crossref","unstructured":"Chebib FT, Hanna C, Harris PC, Torres VE, Dahl NK. Autosomal dominant polycystic kidney disease: A review. JAMA; 2025.","DOI":"10.1001\/jama.2025.0310"},{"issue":"1","key":"4217_CR10","doi-asserted-by":"publisher","first-page":"2492374","DOI":"10.1080\/0886022X.2025.2492374","volume":"47","author":"AH Borghol","year":"2025","unstructured":"Borghol AH, Bou Antoun MT, Hanna C, Salih M, Rahbari-Oskoui FF, Chebib FT. Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances. Ren Fail. 2025;47(1):2492374.","journal-title":"Ren Fail"},{"issue":"6","key":"4217_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","volume":"16","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol. 2021;16(6):908\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4217_CR12","doi-asserted-by":"crossref","unstructured":"Nowak KL, Copeland TP, Ku E, Sarnak MJ, Gitomer B, Abebe KZ, et al. Overweight and obesity and progression to end-stage kidney disease in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2025.","DOI":"10.2215\/CJN.0000000640"},{"issue":"1","key":"4217_CR13","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","volume":"25","author":"K Hopp","year":"2022","unstructured":"Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, et al. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022;25(1):103697.","journal-title":"iScience"},{"issue":"24","key":"4217_CR14","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255\u201366.","journal-title":"N Engl J Med"},{"issue":"10","key":"4217_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.ekir.2023.07.017","volume":"8","author":"PS Sagar","year":"2023","unstructured":"Sagar PS, Rangan GK. Cardiovascular manifestations and management in ADPKD. Kidney Int Rep. 2023;8(10):1924\u201340.","journal-title":"Kidney Int Rep"},{"key":"4217_CR16","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","volume":"69","author":"JC Ribeiro-Silva","year":"2023","unstructured":"Ribeiro-Silva JC, Tavares CAM, Girardi ACC. The blood pressure Lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. Curr Opin Pharmacol. 2023;69:102355.","journal-title":"Curr Opin Pharmacol"},{"key":"4217_CR17","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. 2023;14:100502.","journal-title":"Am J Prev Cardiol"},{"issue":"10","key":"4217_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.bbadis.2011.06.012","volume":"1812","author":"J Norman","year":"2011","unstructured":"Norman J. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta. 2011;1812(10):1327\u201336.","journal-title":"Biochim Biophys Acta"},{"key":"4217_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2018.03.004","volume":"131","author":"YK Li","year":"2018","unstructured":"Li YK, Ma DX, Wang ZM, Hu XF, Li SL, Tian HZ, Wang MJ, Shu YW, Yang J. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis. Pharmacol Res. 2018;131:102\u201311.","journal-title":"Pharmacol Res"},{"issue":"2","key":"4217_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23876\/j.krcp.22.001","volume":"41","author":"JH Yu","year":"2022","unstructured":"Yu JH, Park SY, Lee DY, Kim NH, Seo JA. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res Clin Pract. 2022;41(2):136\u201349.","journal-title":"Kidney Res Clin Pract"},{"key":"4217_CR21","doi-asserted-by":"publisher","unstructured":"Wu J, Cheng S, Zhang Y, Li X, Zhou X, Li X. Glucagon-Like peptide 1 receptor agonist (GLP-1 RA) delays cyst growth in ADPKD: TH-PO456. J Am Soc Nephrol. 2024;35(10S). https:\/\/doi.org\/10.1681\/ASN.2024nt1689gak1682z.","DOI":"10.1681\/ASN.2024nt1689gak1682z"},{"issue":"6","key":"4217_CR22","doi-asserted-by":"publisher","first-page":"F1519","DOI":"10.1152\/ajprenal.00211.2018","volume":"315","author":"BP Dieter","year":"2018","unstructured":"Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Ren Physiol. 2018;315(6):F1519\u201325.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"10","key":"4217_CR23","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","volume":"1812","author":"DP Wallace","year":"2011","unstructured":"Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta. 2011;1812(10):1291\u2013300.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"4217_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1053\/j.ajkd.2024.02.014","volume":"84","author":"KL Nowak","year":"2024","unstructured":"Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, et al. Visceral adiposity and progression of ADPKD: A cohort study of patients from the TEMPO 3:4 trial. Am J Kidney Dis. 2024;84(3):275\u2013e285271.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"4217_CR25","doi-asserted-by":"publisher","first-page":"e0289616","DOI":"10.1371\/journal.pone.0289616","volume":"18","author":"C Liao","year":"2023","unstructured":"Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE. 2023;18(8):e0289616.","journal-title":"PLoS ONE"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04217-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04217-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04217-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:27:11Z","timestamp":1749054431000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04217-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4217"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04217-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}